Eli Lilly scales back planned Mounjaro price rise after backlash

Eli Lilly has trimmed the effective price increase for its popular weight-loss injection Mounjaro after backlash from patients and private providers, documents seen by the Daily Mail show.

The pharmaceutical company had announced earlier this month that wholesale list prices would more than double from Sept. 1, with the highest-strength pen rising from about £122 to £330 a month and a mid-range 5mg pen set to jump from roughly £92 to £180. But commercial arrangements negotiated between Lilly and a number of pharmacists and private clinics mean the top dose will instead cost £247.50—nearly £100 less than the new list price—with smaller discounts applied to lower strengths.

Under the agreements, pharmacies and private providers have committed to buy at negotiated rates from Lilly and are expected to pass those savings on to patients when the change takes effect. In a statement provided to media, Lilly said: "We are working with private providers on commercial arrangements to maintain affordability and expect these to be passed onto patients when the change is effective on 1 September. We are already seeing providers respond in different ways to the list price change, with a range of options available for eligible patients."

The drug, which has been widely prescribed off-label for weight loss and has been dubbed the "King Kong" weight-loss jab in some coverage, sparked concern among users after the company announced the planned price increases. Reports said that some people rushed to buy or stockpile months' supplies of Mounjaro ahead of the September price change to avoid higher costs.

The revised pricing revealed in the documents mitigates but does not eliminate an increase for many patients, and individual costs will vary depending on the negotiated discounts pharmacies and clinics apply. Lilly said the commercial arrangements are intended to maintain affordability; it did not disclose the number of providers participating or the full range of discounts in public statements.

Analysts and providers have previously warned that higher wholesale list prices can ripple through both private-pay markets and insurance reimbursement, affecting access and out-of-pocket costs. Private clinics that prescribe and dispense Mounjaro directly to patients have been among the most vocal about potential disruptions if list prices rose sharply.

The company’s move to offer commercial arrangements comes as demand for GLP-1 class drugs such as tirzepatide — marketed by Lilly as Mounjaro — has surged amid growing public interest in pharmaceutical weight-loss treatments. The market dynamics have prompted scrutiny from patients, clinicians and some policymakers about affordability and equitable access.

Lilly’s statement suggested a range of provider responses to the list-price change, but it did not provide a timeline for whether or how discounts would be standardized across providers. Patients seeking treatment through private clinics or community pharmacies were advised to check with their provider about final dispensing prices for specific pen strengths when the September change takes effect.

As of publication, Lilly and a representative sample of private providers had not released detailed, publicly available price lists reflecting the negotiated rates for all strengths. The company’s announcement and subsequent commercial arrangements signal a partial retreat from the initially advertised wholesale increases, while leaving variability in what individual patients ultimately will pay.